This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Pinealon (20 mg Vial)
Pinealon is a synthetic tripeptide bioregulator (GluAspArg) developed as part of Professor Vladimir Khavinson’s extensive peptide research program[1][2]. This neuroprotective peptide is studied for its ability to protect neurons from oxidative stress, support cognitive function, and modulate gene expression in brain tissue[3][4].
Quick Reference
What is Pinealon?
Research overview based on the cited scientific literature.
• Goal: Support neuroprotection, cognitive function, and cellular resilience in brain tissue through peptide bioregulation[3][7].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Pinealon studied?
EDR/Pinealon has been studied in cell and model systems for possible effects on gene expression and protein synthesis related to neurodegeneration[4]. This is mechanistic evidence and does not establish a clinical dosing schedule. Research indicates it reduces reactive oxygen species accumulation and necrotic cell death in neurons while modulating the cell cycle to activate proliferative pathways[3][8]. Preclinical studies demonstrate neuroprotective effects against oxidative stress, ischemic injury, and cognitive decline, with improvements in memory retention and learning capacity observed in animal models[9][10]. Clinical trials in humans with traumatic brain injury and cerebral disorders have reported improvements in memory, attention, cognitive function, and emotional stability with daily administration of oral or injectable Pinealon[6][11].
What does the research report about Pinealon?
Observations from preclinical and clinical literature.
• Neuroprotective effects through reduction of oxidative stress and preservation of neuronal viability[3][9].
• Improvements in memory, learning capacity, and cognitive function in both animal and human studies[6][10][11].
• Modulation of caspase3 activity may reduce apoptosis in neurons and other tissues[12][13].
• Established pineal physiology links melatonin secretion to the light-dark cycle[14]. Pinealon research should use those measurable circadian endpoints when evaluating pineal-function claims.
• Generally well tolerated; occasional mild injectionsite reactions (redness, itching) may occur with subcutaneous administration[15].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Pinealon?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.